Moderna said on Feb. 23 that it recently reached a patent agreement with the U.S. government over disputed technology that is featured in its COVID-19 vaccine.
In December 2022, Moderna entered “a nonexclusive patent license agreement” with the National Institute of Allergy and Infectious Diseases (NIAID), said CFO Jamey Mock during an earnings call on Thursday.